Effect of Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertension and Hypertriglyceridemia

Jun Hwan Cho; Young Hwan Choi; Cheol Won Hyeon; Kyung Joon Kim; Seonghyup Hyun; Jee Eun Kwon; Eun Young Kim; Wang-Soo Lee; Kwang Je Lee; Sang-Wook Kim; Tae Ho Kim; Chee Jeong Kim

doi:10.12997/jla.2013.2.1.19

Journal List > J Lipid Atheroscler > v.2(1) > 1059524

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Cho, Choi, Hyeon, Kim, Hyun, Kwon, Kim, Lee, Lee, Kim, Kim, and Kim: Effect of Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertension and Hypertriglyceridemia

Original Article

Journal of Lipid and Atherosclerosis 2013; 2(1): 19-26.

Published online: 15 May 2013

DOI: https://doi.org/10.12997/jla.2013.2.1.19

Effect of Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertension and Hypertriglyceridemia

Jun Hwan Cho, Young Hwan Choi, Cheol Won Hyeon, Kyung Joon Kim, Seonghyup Hyun, Jee Eun Kwon, Eun Young Kim, Wang-Soo Lee, Kwang Je Lee, Sang-Wook Kim, Tae Ho Kim, Chee Jeong Kim

Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea.

Corresponding Author: Chee Jeong Kim, Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University, 224-1 Heukseok-dong, Dongjak-gu, Seoul 156-755, Korea. Tel: +82-2-6299-1398, Fax: +82-2-822-2769, cjkim@cau.ac.kr

Received 25 April 2013 Revised 6 May 2013 Accepted 8 May 2013

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective

Previous studies have reported that fenofibrate therapy increased blood creatinine levels. We investigated the effect of fenofibrate therapy on creatinine levels in patients with hypertension and hypertriglyceridemia.

Methods

This retrospective study included 36 hypertensive patients with hypertriglyceridemia taking fenofibrate for 1-3 years (Fenofibrate group) and 36 control patients with similar age, sex, follow-up duration, creatinine levels, and lipid levels to those of fenofibrate therapy (Control group).

Results

Baseline parameters except lipid profiles were similar between the fenofibrate and control groups. Creatinine levels increased in the fenofibrate group (from 0.90±0.18 mg/dL to 1.05±0.22 mg/dL, p<0.001) and did not change in the control group (from 0.91±0.12 mg/dL to 0.92±0.14 mg/dL, p=0.39). The elevation was more pronounced in the fenofibrate group than in the control group (0.15±0.12 vs. 0.02±0.11 mg/dL, p<0.001). Changes in creatinine levels were only associated with fenofibrate therapy (r=0.52, p<0.001) in the stepwise linear regression analysis.

Conclusion

Fenofibrate therapy for 1-3 years significantly increased creatinine levels in hypertensive patients with hypertriglyceridemia. This finding suggests that follow-up measurement of creatinine level is necessary with fenofibrate therapy.

Keywords: Fenofibrate, Creatinine, Hypertension, Hypertriglyceridemia

Figures and Tables

Fig. 1

Changes of creatinine levels in control (A) and fenofibrate groups (B)

Table 1

Comparisons of baseline demographic and clinical characteristics between control and fenofibrate groups

ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker

Table 2

Comparisons of baseline laboratory findings between control and fenofibrate groups

BUN: blood urea nitrogen, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ^*: p<0.05 vs Pre-Tx, ^**: patients with TG <400 mg/dL

Table 3

Comparisons of percent changes in renal functions and lipid profiles between control and fenofibrate groups

BUN: blood urea nitrogen, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, ^*: control versus fenofibrate groups, ^**: baseline versus follow-up, ^***: in patients with TG <400 mg/dL

References

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267–1278.

2. Kim CJ, Lee KJ. Hypercholesterolemia; management of Korean patients in new millennium. Korean J Med. 2007; 72:580–592.

3. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol. 2007; 99:732–738.

4. Cho JH, Kim KJ, Lee WS, Lee KJ, Kim SW, Kim TH, Kim CJ. Effect of statins on C-reactive protein, lipoprotein(a) and fibrinogen in hypercholesterolemic patients. J Lipid Atheroscler. 2012; 1:21–28.

5. Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis. 2010; 210:35–40.

6. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009; 122:962.e1–962.e8.

7. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007; 99:3C–18C.

8. Lageder H. Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia. Wien Klin Wochenschr. 1980; 92:95–101.

9. Dick TB, Marples J, Ledermann HM, Whittington J. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. Curr Med Res Opin. 1981; 7:489–502.

10. Rössner S, Orö L. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate. Atherosclerosis. 1981; 38:273–282.

11. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronaryartery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; 357:905–910.

12. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849–1861.

13. ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563–1574.

14. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007; 370:591–603.

15. Hopkins PN, Hunt SC, Wu LL, Williams GH, Williams RR. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Curr Opin Lipidol. 1996; 7:241–253.

16. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000; 15:1993–1999.

17. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92:536–541.

18. Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy. 2001; 21:1145–1149.

19. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol. 2001; 12:341–348.

20. Ansquer JC, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008; 51:904–913.

21. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA. 1997; 278:2069–2074.

22. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999; 341:1127–1133.

23. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC. Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011; 54:280–290.

24. Williams AJ, Baker F, Walls J. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. Br J Clin Pharmacol. 1984; 18:361–367.

25. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92:536–541.

26. Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am J Kidney Dis. 2004; 44:543–550.

27. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999; 354:219–220.

TOOLS

Similar articles